Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 AIDS Res Hum Retroviruses
3 Ann Intern Med
1 BMC Pediatr
6 Clin Infect Dis
1 J Immunol
1 J Infect
4 J Infect Dis
2 J Virol
1 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
3 Nat Med
1 Pediatr Infect Dis J
3 Pediatrics
1 PLoS Med
14 PLoS One
2 Proc Natl Acad Sci U S A
3 Science
24 Vaccine
1 Virology
2 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AIDS Res Hum Retroviruses

  1. LAHER F, Richardson SI, Smith P, Sullivan P, et al
    HIV prevention in a time of COVID-19: A report from the HIVR4P // Virtual conference 2021.
    AIDS Res Hum Retroviruses. 2021 Oct 29. doi: 10.1089/AID.2021.0138.
    PubMed         Abstract available

    Ann Intern Med

  2. ROSENBLUM HG, Lewis RM, Gargano JW, Querec TD, et al
    Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M21-3798.
    PubMed         Abstract available

  3. PERKINS RB, Saslow D, Oliver K
    Long-Term Effectiveness of Human Papillomavirus Vaccination: Implications for Future Reduction in Cancer.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-1309.

  4. ASSOUMOU SA, Peterson A, Ginman E, James T, et al
    Addressing Inequities in SARS-CoV-2 Vaccine Uptake: The Boston Medical Center Health System Experience.
    Ann Intern Med. 2022 May 17. doi: 10.7326/M22-0028.
    PubMed         Abstract available

    BMC Pediatr

  5. MULUYE M, Oljira L, Eyeberu A, Getachew T, et al
    Partial vaccination and associated factors among children aged 12-23 months in eastern Ethiopia.
    BMC Pediatr. 2022;22:268.
    PubMed         Abstract available


  6. WISE J
    NICE publishes guidance to increase uptake of routine vaccinations.
    BMJ. 2022;377:o1260.

  7. SIVAN M, Greenhalgh T, Milne R, Delaney B, et al
    Are vaccines a potential treatment for long covid?
    BMJ. 2022;377:o988.

  8. HOANG U, de Lusignan S, Joy M, Sherlock J, et al
    Future reporting of vaccine uptake needs to include any change in ethnic or socioeconomic disparities.
    BMJ. 2022;377:o1233.

  9. AYOUBKHANI D, Bermingham C, Pouwels KB, Glickman M, et al
    Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study.
    BMJ. 2022;377:e069676.
    PubMed         Abstract available

    Clin Infect Dis

  10. BARI A, Heymann M, Cohen RJ, Zhao R, et al
    Exploring Coronavirus Disease 2019 Vaccine Hesitancy on Twitter Using Sentiment Analysis and Natural Language Processing Algorithms.
    Clin Infect Dis. 2022;74.
    PubMed         Abstract available

  11. WEITZMAN ER, Sherman AC, Levy O
    Pediatric SARS-CoV-2 Vaccines: Perceptions and Attitudes from the FDA Public Commentary.
    Clin Infect Dis. 2022 May 17. pii: 6586838. doi: 10.1093.
    PubMed         Abstract available

  12. WEITZMAN ER, Kossowsky J, Blakemore LM, Cox R, et al
    Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making.
    Clin Infect Dis. 2022 May 17. pii: 6586840. doi: 10.1093.
    PubMed         Abstract available

  13. MARTINUZZI E, Benzaquen J, Guerin O, Leroy S, et al
    A Single Dose of BNT162b2 mRNA Vaccine Induces Airway Immunity in SARS-CoV-2 Naive and recovered COVID-19 subjects.
    Clin Infect Dis. 2022 May 17. pii: 6586846. doi: 10.1093.
    PubMed         Abstract available

  14. TENFORDE MW, Self WH, Zhu Y, Naioti EA, et al
    Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States.
    Clin Infect Dis. 2022 May 17. pii: 6587132. doi: 10.1093.
    PubMed         Abstract available

  15. LEVIN-RECTOR A, Firestein L, McGibbon E, Sell J, et al
    Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults, July-November 2021.
    Clin Infect Dis. 2022 May 20. pii: 6589783. doi: 10.1093.
    PubMed         Abstract available

    J Immunol

  16. JERGOVIC M, Coplen CP, Uhrlaub JL, Beitel SC, et al
    Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved.
    J Immunol. 2022;208:2461-2465.
    PubMed         Abstract available

    J Infect

  17. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.

    J Infect Dis

  18. NALIN D
    Cholera control requires reducing mortality along with vaccination programs.
    J Infect Dis. 2022 May 18. pii: 6588066. doi: 10.1093.

  19. AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
    Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
    J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.

  20. AZIZ AB, Verma H, Jeyaseelan V, Md Y, et al
    One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomized clinical trial in Bangladesh.
    J Infect Dis. 2022 May 16. pii: 6586252. doi: 10.1093.
    PubMed         Abstract available

  21. FAUSTHER-BOVENDO H, Qiu X, Babuadze GG, Azizi H, et al
    Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
    J Infect Dis. 2022;225:1852-1855.
    PubMed         Abstract available

    J Virol

  22. KIRKPATRICK ROUBIDOUX E, Sano K, McMahon M, Carreno JM, et al
    Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies.
    J Virol. 2022 Apr 21:e0033222. doi: 10.1128/jvi.00332.
    PubMed         Abstract available

  23. LUCAS CJ, Davenport BJ, Carpentier KS, Tinega AN, et al
    Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
    J Virol. 2022;96:e0006422.
    PubMed         Abstract available


  24. FLEMING-DUTRA KE, Britton A, Shang N, Derado G, et al
    Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    JAMA. 2022 May 13. pii: 2792524. doi: 10.1001/jama.2022.7493.
    PubMed         Abstract available

  25. DORABAWILA V, Hoefer D, Bauer UE, Bassett MT, et al
    Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant.
    JAMA. 2022 May 13. pii: 2792525. doi: 10.1001/jama.2022.7319.

    MMWR Morb Mortal Wkly Rep

  26. RACHLIN A, Patel JC, Burns CC, Jorba J, et al
    Progress Toward Polio Eradication - Worldwide, January 2020-April 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:650-655.
    PubMed         Abstract available

    N Engl J Med

  27. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
    PubMed         Abstract available

  28. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
    Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.

    Nat Med

  29. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.

  30. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    PubMed         Abstract available

  31. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    PubMed         Abstract available

    Pediatr Infect Dis J

  32. HEININGER U, Plotkin S
    Titerphilia - The Irresistible Urge to Measure Postimmunization Antibody Values.
    Pediatr Infect Dis J. 2022;41:490-491.
    PubMed         Abstract available


  33. NYGAARD U, Holm M, Dungu KHS, Matthesen AT, et al
    Risk of Myopericarditis After COVID-19 Vaccination in Danish Children Aged 5-11 Years.
    Pediatrics. 2022 May 19. pii: 188025. doi: 10.1542/peds.2022-057508.
    PubMed         Abstract available

  34. HAUSE AM, Shay DK, Klein NP, Abara WE, et al
    Safety of COVID-19 Vaccination in US Children Ages 5-11 Years.
    Pediatrics. 2022 May 18. pii: 188023. doi: 10.1542/peds.2022-057313.
    PubMed         Abstract available

  35. OLIVER SE, Wallace M, Link-Gelles R
    COVID-19 Vaccines: Safe and Effective in Children Ages 5-11 Years.
    Pediatrics. 2022 May 18. pii: 188024. doi: 10.1542/peds.2022-057314.
    PubMed         Abstract available

    PLoS Med

  36. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    PubMed         Abstract available

    PLoS One

  37. BUTLER JZ, Carson M, Rios-Fetchko F, Vargas R, et al
    COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysis.
    PLoS One. 2022;17:e0266397.
    PubMed         Abstract available

    It's Time to be disgusting about COVID-19: Effect of disgust priming on COVID-19 public health compliance among liberals and conservatives.
    PLoS One. 2022;17:e0267735.
    PubMed         Abstract available

  39. SEREDA AD, Kazakova AS, Dmitrenko VV, Kolbasov DV, et al
    Search for additional tests for immunobiological evaluation of the candidate vaccines against African swine fever.
    PLoS One. 2022;17:e0265819.
    PubMed         Abstract available

  40. WINARTO H, Habiburrahman M, Dorothea M, Wijaya A, et al
    Knowledge, attitudes, and practices among Indonesian urban communities regarding HPV infection, cervical cancer, and HPV vaccination.
    PLoS One. 2022;17:e0266139.
    PubMed         Abstract available

  41. EL DEEB O, Jalloul M
    Efficacy versus abundancy: Comparing vaccination schemes.
    PLoS One. 2022;17:e0267840.
    PubMed         Abstract available

  42. IWAMOTO M, Ukimura A, Ogawa T, Kawanishi F, et al
    Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
    PLoS One. 2022;17:e0268529.
    PubMed         Abstract available

  43. ACKAH M, Ameyaw L, Gazali Salifu M, Afi Asubonteng DP, et al
    COVID-19 vaccine acceptance among health care workers in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0268711.
    PubMed         Abstract available

  44. GUZMAN-HOLST A, Luna-Casas G, Burguete Garcia A, Madrid-Marina V, et al
    Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study.
    PLoS One. 2022;17:e0268469.
    PubMed         Abstract available

  45. WITUS LS, Larson E
    A randomized controlled trial of a video intervention shows evidence of increasing COVID-19 vaccination intention.
    PLoS One. 2022;17:e0267580.
    PubMed         Abstract available

  46. BONNER KE, Ssekyanzi H, Sicsic J, Mueller JE, et al
    What drives willingness to receive a new vaccine that prevents an emerging infectious disease? A discrete choice experiment among university students in Uganda.
    PLoS One. 2022;17:e0268063.
    PubMed         Abstract available

  47. OSUJI VC, Galante EM, Mischoulon D, Slaven JE, et al
    COVID-19 vaccine: A 2021 analysis of perceptions on vaccine safety and promise in a U.S. sample.
    PLoS One. 2022;17:e0268784.
    PubMed         Abstract available

  48. DAZA-TORRES ML, Garcia YE, Schmidt AJ, Pollock BH, et al
    The impact of COVID-19 vaccination on California's return to normalcy.
    PLoS One. 2022;17:e0264195.
    PubMed         Abstract available

  49. SSEKAMATTE T, Isunju JB, Mutyoba JN, Tetui M, et al
    Predictors of Hepatitis B screening and vaccination status of young psychoactive substance users in informal settlements in Kampala, Uganda.
    PLoS One. 2022;17:e0267953.
    PubMed         Abstract available

  50. MURUGESAN M, Mathews P, Paul H, Karthik R, et al
    Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India.
    PLoS One. 2022;17:e0268797.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  51. BAXTER-KING R, Brown JR, Enos RD, Naeim A, et al
    How local partisan context conditions prosocial behaviors: Mask wearing during COVID-19.
    Proc Natl Acad Sci U S A. 2022;119:e2116311119.
    PubMed         Abstract available

  52. KINGSTAD-BAKKE B, Lee W, Chandrasekar SS, Gasper DJ, et al
    Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Proc Natl Acad Sci U S A. 2022;119:e2118312119.
    PubMed         Abstract available


    Wrestling with bird flu, Europe considers once-taboo vaccines.
    Science. 2022;376:682-683.
    PubMed         Abstract available

  54. DOLGIN E
    Better lipids to power next generation of mRNA vaccines.
    Science. 2022;376:680-681.
    PubMed         Abstract available

  55. VOGEL G
    New subvariants are masters of immune evasion.
    Science. 2022;376:679-680.
    PubMed         Abstract available


  56. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    PubMed         Abstract available

  57. NAZURDINOV A, Azizov Z, Mullojonova M, Sadykova U, et al
    Impact and effectiveness of monovalent rotavirus vaccine in Tajik children.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00589.
    PubMed         Abstract available

  58. SULIS G, Horn M, Borrow R, Basta NE, et al
    A comparison of national vaccination policies to prevent serogroup B meningococcal disease.
    Vaccine. 2022 May 14. pii: S0264-410X(22)00568.
    PubMed         Abstract available

  59. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    PubMed         Abstract available

  60. POLAND GA, van Dijk N
    John D. Bailey retiring after more than 20years of service to Vaccine.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00618.

  61. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    PubMed         Abstract available

  62. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    PubMed         Abstract available

  63. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    PubMed         Abstract available

  64. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    PubMed         Abstract available

  65. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    PubMed         Abstract available

  66. LI F, Freed D, Heidecker G, Galli J, et al
    A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00569.
    PubMed         Abstract available

  67. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    PubMed         Abstract available

  68. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    PubMed         Abstract available

  69. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.

  70. OSMAN S, Crowcroft N, McLachlan E, Hatchette T, et al
    Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2022;40:3228-3235.
    PubMed         Abstract available

  71. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed         Abstract available

  72. ZOLA MATUVANGA T, Lariviere Y, Lemey G, De Bie J, et al
    Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00544.
    PubMed         Abstract available

  73. MARTIN J, Barrett ADT, Lei D, Minor P, et al
    WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
    Vaccine. 2022 May 9. pii: S0264-410X(22)00548.
    PubMed         Abstract available

  74. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    PubMed         Abstract available

  75. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    PubMed         Abstract available

  76. ISLAM N, Xu C, Lau CL, Mills DJ, et al
    Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00535.
    PubMed         Abstract available

  77. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed         Abstract available

  78. FERNANDES C, Alves J, Rodrigues A, Azevedo J, et al
    Corrigendum to "Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study" [Vaccine 40(2) (2022) 275-281].
    Vaccine. 2022 May 11. pii: S0264-410X(22)00537.

  79. SHAUM A, Mujuru HA, Takamiya M, Ticklay I, et al
    Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00551.
    PubMed         Abstract available


  80. KHAN K, Khan SA, Jalal K, Ul-Haq Z, et al
    Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
    Virology. 2022;572:28-43.
    PubMed         Abstract available

    Virus Res

  81. LI J, Li S, Qiu M, Li X, et al
    Minor and major envelope proteins of PRRSV play synergistic roles in inducing heterologous neutralizing antibodies and conferring cross protection.
    Virus Res. 2022;315:198789.
    PubMed         Abstract available

  82. ROWLAND RRR, Doerksen T, Lu A, Sheahan M, et al
    Effect of the host genotype at a Porcine Reproductive and Respiratory Syndrome (PRRS) resistance marker on evolution of the modified-live PRRS vaccine virus in pigs.
    Virus Res. 2022;316:198809.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.